Cenicriviroc is a benzazocine derivative with the structure (5Z)-1,2,3,4-tetrahydro-1-benzazocine substituted at positions 1, 5, and 8 by a 2-methylpropyl group, an N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide group, and a 4-(2-butoxyethoxy)phenyl group, respectively. It is a potent chemokine receptor 2 and 5 antagonist under development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It functions as a chemokine receptor 5 antagonist, an anti-HIV agent, a chemokine receptor 2 antagonist, an antirheumatic drug, and an anti-inflammatory agent. It is classified as a diether, imidazole, sulfoxide, aromatic ether, secondary carboxamide, and benzazocine.
